{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_references_citation in Reference Text / Citation (approximate match)
Status:
US Previously Marketed
First approved in 1958
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02131220: Phase 4 Interventional Completed Myocardial Infarction
(2015)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02234869: Phase 4 Interventional Withdrawn Relapsing Multiple Sclerosis
(2014)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04595877: Phase 4 Interventional Completed Pain
(2006)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04244383: Phase 4 Interventional Unknown status Hepatitis C
(2020)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Other
Class:
POLYMER
